Skip to main content

Table 2 Correlation between ADAM10 expression and clinic pathological factors in 94 breast cancer tissues

From: ADAM10 is involved in the oncogenic process and chemo-resistance of triple-negative breast cancer via regulating Notch1 signaling pathway, CD44 and PrPc

Factors

ADAM10 expression

Univariate analysis

Multivariate analysis

Low (mean ± SE)

High (mean ± SE)

p-value

OR (95%CI)

p-value

OR (95%CI)

p-value

Age at diagnosis (years)

 < 55

34 (120.4 ± 54.60)

15 (252.0 ± 34.58)

0.008**

0.35 (0.12–1.00)

0.050

0.96 (0.19–4.77)

0.963

 ≥ 55

39 (91.2 ± 62.02)

6 (297.5 ± 6.12)

     

Menopause

Yes

53 (98.9 ± 62.35)

10 (277.5 ± 27.61)

0.024*

0.34 (0.13–0.93)

0.036*

0.45 (0.05–0.53)

0.292

No

20 (120.5 ± 51.9)

11 (253.6 ± 39.94)

     

BMI (kg/m2)

 > 23

51 (106.7 ± 56.50)

6 (245.0 ± 37.55)

0.023*

5.80 (1.99–16.91)

0.001**

0.17 (0.10–2.00)

0.002**

 ≤ 23

22 (100.5 ± 68.97)

15 (273.0 ± 33.16)

     

Histological grade

I

4 (95.0 ± 72.23)

2 (262.5 ± 53.03)

0.172

0.55 (0.18–1.65)

0.286

  

II

56 (98.4 ± 59.23)

17 (270.0 ± 34.37)

     

III

13 (135.4 ± 55.28)

2 (225.0 ± 21.21)

     

Tumor size

T1

4 (78.8 ± 55.43)

2 (262.5 ± 53.03)

0.683

0.89 (0.29–2.76)

0.846

  

T2

60 (104.8 ± 62.52)

16 (266.3 ± 37.35)

     

T3

9 (116.1 ± 45.26)

3 (260.0 ± 31.22)

     

Distant metastasis (before NACT)

Yes

4 (107.5 ± 70.77)

3 (300)

0.287

0.56 (0.06–4.92)

0.599

  

No

53 (109.7 ± 63.91)

16 (282.2 ± 21.37)

     

Regional lymphatic metastasis (after NACT)

Yes

38 (103.3 ± 62.63)

9 (283.3 ± 21.79)

0.066

1.42 (0.52–3.83)

0.492

  

No

19 (122.1 ± 65.77)

10 (286.5 ± 20.55)

     

Response to NACT

Good

58 (99.5 ± 59.41)

11 (285 ± 27.66)

0.023*

0.28 (0.10–0.79)

0.016*

0.29 (0.44–16.22)

0.042*

Poor

15 (125.3 ± 60.34)

10 (243.0 ± 31.46)

     
  1. OR odds ratio, CI confidence interval
  2. *p < 0.05, **p < 0.01